Levosimendan Reig Jofre

Levosimendan, the active ingredient in Levosimendan Reig Jofre, is a calcium sensitizer presented as an intravenous solution for intravenous use. It improves cardiac contractility and reduces vascular resistance, helping patients with acute decompensated heart failure.

GNH USA supplies Levosimendan Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and cardiac care centres worldwide.

Levosimendan is indicated for conditions affecting cardiac output and systemic perfusion.

Acute decompensated heart failure: enhances myocardial contractility and lowers filling pressures, improving symptoms and haemodynamics. Chronic severe heart failure (inotropic support): provides temporary haemodynamic stabilisation when conventional therapy is insufficient. Post‑cardiac surgery low‑output syndrome: assists in stabilising haemodynamics during early recovery.

Levosimendan may be associated with a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, may be transient. - Hypotension: reduction in blood pressure, especially with rapid infusion. - Tachycardia: increased heart rate. - Arrhythmia: occasional ectopic beats. - Flushing: warm sensation and reddening of skin.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischaemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: increased transaminases. - Thrombocytopenia: reduced platelet count.

Levosimendan should be used with careful clinical monitoring.

Renal impairment: monitor renal function and adjust infusion as needed. Hepatic impairment: use with caution; observe liver enzymes. Hypotension: avoid rapid bolus; continuously monitor blood pressure. Concurrent vasodilators: may amplify hypotensive effect. Pregnancy: safety unknown; prescribe only if benefit outweighs risk. Store below 25°C: keep in original container, protect from light and moisture.

Levosimendan can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Strong CYP450 inhibitors (e.g., ketoconazole): can raise plasma levosimendan levels. - Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response; monitor haemodynamics. - Diuretics: can worsen electrolyte disturbances; check electrolytes regularly. - Anticoagulants: monitor for bleeding if hypotension occurs.